ALRN-6924 is a p53-reactivating peptide that demonstrated enhancement of the anti-cancer immune response even in the absence of immunotherapy in vivo. There are two completed (NCT02264613, NCT02909972) and two active (NCT03654716, NCT03725436) clinical trials evaluating this peptide, though none note an intention to evaluate the immune response to treatment (Zhou et al., 2021). Here, TP53 is linked to cancer.